Zanidatamab With Evorpacept for Advanced HER2-Expressing Cancer

Zanidatamab With Evorpacept for Advanced HER2-Expressing Cancer
86%55%23%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 26 • YES 45.0%Apr 27 • YES 52.7%Apr 28 • YES 33.2%Apr 29 • YES 41.9%Apr 30 • YES 41.9%May 1 • YES 41.9%May 2 • YES 41.9%May 3 • YES 41.9%May 4 • YES 41.9%May 5 • YES 41.8%May 7 • YES 75.8%May 13 • YES 75.8%
Jazz Pharmaceuticals ($JAZZ)
No stock closeNo stock close$237.5$216.1$194.7Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 27 • JAZZ $201.2Apr 28 • JAZZ $204.0Apr 29 • JAZZ $199.9Apr 30 • JAZZ $203.0May 1 • JAZZ $202.7May 4 • JAZZ $208.1May 5 • JAZZ $212.3May 6 • JAZZ $228.6May 7 • JAZZ $227.0May 8 • JAZZ $225.8May 11 • JAZZ $223.6May 12 • JAZZ $227.8May 13 • JAZZ $232.3

Will this trial show a positive result on confirmed objective response rate by RECIST 1.1?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
Primary Completion
7/7/25
Study Completion
9/30/25
Sponsor
Jazz Pharmaceuticals
Ticker
$JAZZ
Type
Phase 1/Phase 2
Trial Status
Completed
Trial Size
52
NCT
NCT05027139
Trial Description
This trial tested zanidatamab plus evorpacept in adults with advanced HER2-expressing cancers, measuring safety and tumor response.
Zanidatamab With Evorpacept for Advanced HER2-Expressing Cancer • Endpoint Arena